Financial Performance - Revenue for Q1 2023 was RMB 168.24 million, a year-on-year increase of 12.06%[6] - Revenue for Q1 2023 increased to RMB 168.24 million, up 12.1% from RMB 150.14 million in Q1 2022[18] - Net loss attributable to shareholders was RMB 323.77 million, with a basic and diluted loss per share of RMB 0.60[6][7] - Net loss for Q1 2023 widened to RMB 323.77 million, compared to RMB 286.83 million in Q1 2022[18] - Basic and diluted earnings per share for Q1 2023 were both negative RMB 0.60, compared to negative RMB 0.59 in Q1 2022[19] - Total comprehensive loss for Q1 2023 was RMB 326.63 million, compared to RMB 287.62 million in Q1 2022[19] - Weighted average return on equity was -6.40%, an increase of 2.28 percentage points[7] Research and Development (R&D) - R&D investment totaled RMB 249.72 million, accounting for 148.43% of revenue, a year-on-year increase of 14.46%[7] - R&D expenses for Q1 2023 rose to RMB 249.72 million, a 14.5% increase from RMB 218.17 million in Q1 2022[18] Cash Flow and Liquidity - The company's cash flow from operating activities was negative RMB 349.85 million[6] - Operating cash flow for Q1 2023 was negative RMB 349.85 million, slightly improved from negative RMB 350.48 million in Q1 2022[20] - Investment cash flow for Q1 2023 was negative RMB 584.09 million, significantly higher than negative RMB 183.07 million in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 decreased to RMB 1.09 billion from RMB 2.07 billion at the beginning of the quarter[21] - Cash received from selling goods and providing services in Q1 2023 was RMB 186.44 million, up 181.0% from RMB 66.34 million in Q1 2022[20] - Monetary funds decreased to 1.25 billion yuan as of March 31, 2023, from 2.19 billion yuan at the end of 2022[15] Assets and Liabilities - Total assets decreased by 5.69% to RMB 5.68 billion compared to the end of the previous year[7] - Total assets decreased to 5.68 billion yuan as of March 31, 2023, from 6.02 billion yuan at the end of 2022[16] - Total liabilities decreased to 997.69 million yuan as of March 31, 2023, from 1.04 billion yuan at the end of 2022[16] - Shareholders' equity decreased by 6.02% to RMB 4.68 billion compared to the end of the previous year[7] - Shareholders' equity decreased to 4.68 billion yuan as of March 31, 2023, from 4.98 billion yuan at the end of 2022[16] - Inventory increased to 624.32 million yuan as of March 31, 2023, from 522.67 million yuan at the end of 2022[16] Shareholders and Equity - The top shareholder, HKSCC NOMINEES LIMITED, holds 34.83% of the shares[10] - Yantai Rongda Venture Capital Center holds 18.81% of the shares, all of which are restricted shares[10] - HKSCC NOMINEES LIMITED holds 189,566,228 unrestricted shares, representing 189,566,228 foreign-listed shares[12] - Total A-share common shareholders: 5,628, H-share common shareholders: 26, totaling 5,654 shareholders[14] - Hua Tai Securities Asset Management - China Merchants Bank - Hua Tai Rongchang Biotech Home 1st Employee Stock Ownership Plan lent out 2 million shares through securities lending[13] Non-Recurring Items - Non-recurring gains and losses amounted to RMB 8.02 million, mainly from government subsidies and financial asset gains[8] Sales and Expenses - Sales expenses for Q1 2023 surged to RMB 157.82 million, a 95.4% increase from RMB 80.78 million in Q1 2022[18]
荣昌生物(09995) - 2023 Q1 - 季度业绩